The efficacy of novel ovarian cancer treatment targeting SIRT1

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K09538
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 56040:Obstetrics and gynecology-related
• Research Institution: Shinshu University
• Principal Investigator: Asaka Ryoichi 信州大学, 学術研究院医学系(医学部附属病院), 助教 (00623688)
• Co-Investigator(Kenkyū-buntansha): 小野 元紀 信州大学, 医学部附属病院, 助教(診療) (10816432) ; 塩沢 丹里 信州大学, 学術研究院医学系, 教授 (20235493)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: SIRT1 / 分子標的薬 / 婦人科悪性腫瘍

Outline of Final Research Achievements

We conducted a study on the effects of a selective SIRT1 inhibitor in ovarian cancer. The selective SIRT1 inhibitor alone did not exhibit antitumor effects on ovarian cancer cell lines, so we examined the combined effect with the existing antitumor drug, cisplatin. No synergistic effect was observed with cisplatin. Therefore, we decided to investigate the effect of SIRT1 on gastric-type adenocarcinoma of the cervix, a condition recently associated with poor prognosis and in need of new treatments. Immunostaining confirmed the expression of SIRT1 protein in gastric-type adenocarcinoma of the cervix.

Free Research Field

婦人科腫瘍学

Academic Significance and Societal Importance of the Research Achievements

卵巣癌に対するSIRT1の抗腫瘍効果については成果が得られなかった。しかし、婦人科癌において、治療選択肢の少ない子宮頸部胃型腺癌におけるSIRT1タンパクの高発現について新しく知見を得ることができた。当教室ではこれまで樹立された細胞株のない子宮頸部胃型腺癌のオルガノイド培養に成功しており、今後この細胞を用いて、あらたな分子標的薬としてSIRT1阻害薬の効果を検討することができる。